De-escalation Protocol. Phase II Study of Low Intensity Allogeneic Stem Cell Transplantation Using a Conditioning Regimen Containing Fludarabine and Melphalan. Effect of Campath-1H Dose Reduction on the Incidence of Graft-Versus-Host Disease and Infecti

Trial Profile

De-escalation Protocol. Phase II Study of Low Intensity Allogeneic Stem Cell Transplantation Using a Conditioning Regimen Containing Fludarabine and Melphalan. Effect of Campath-1H Dose Reduction on the Incidence of Graft-Versus-Host Disease and Infecti

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Hodgkin's disease; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Sep 2015 Accrual to date is 107% as reported by United Kingdom Clinical Research Network record.
    • 13 Mar 2012 Status changed from active, no longer recruiting to completed as reported by UKCRN.
    • 07 Apr 2009 Additional lead trial centres Schering Health Care Ltd, University College London reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top